Renal thromboembolism during treatment with recombinant activated factor VII (rFVIIa) in a child with hemophilia B with factor IX inhibitors.

Abstract

BACKGROUND:

Serious thromboembolic events connected with rFVIIa therapy in hemophilia patients are rare. Only three cases are reported in children, all of them with hemophilia A.

CASE PRESENTATION:

We present unique case of patient with hemophilia B and high titer inhibitors to coagulation FIX, who developed severe renal damage due to thromboembolic event during rFVIIa therapy, associated with unsuspected renovascular anomalies.

CONCLUSION:

Caution is necessary if hematuria B requires administration of rFVIIa. US color doppler renal imaging before and after drug administration should be sufficient as an early warning.

• Authors: Danko Milošević, Ernest Bilić, Danica Batinić, Mirjana Poropat, Ranka Štern-Padovan, Slobodan Galić, Daniel Turudić
• Journal: BMC pediatrics (BMC Pediatr) Vol. 14 Pg. 315 (Dec 17 2014) ISSN: 1471-2431 [Electronic] England
• PMID: 25515020 (Publication Type: Case Reports, Journal Article)

Chemical References

• Blood Coagulation Factor Inhibitors
• Recombinant Proteins
• Factor IX
• recombinant FVIIa
• Factor VIIa

Topics

• Blood Coagulation Factor Inhibitors (metabolism)
• Child
• Factor IX (antagonists & inhibitors)
• Factor VIIa (adverse effects)
• Hematuria (blood, drug therapy)
• Hemophilia B (blood, drug therapy)
• Humans
• Kidney (blood supply)
• Male
• Recombinant Proteins (adverse effects)
• Thromboembolism (chemically induced)